Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5780)
All Articles published online
|
Sep 28, 2009 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009; 15(36): 4511-4517 [PMID: 19777609 DOI: 10.3748/wjg.15.4511] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i36/4511.htm |
| Number | Citing Articles |
| 1 |
Sumaira Qayoom, Apoorva Agarwal, Preeti Agarwal, Akshay Anand, Rashmi Raj, Sameer Gupta, Ajay Singh. Evaluation of HER2Neu Status in Periampullary Cancers in Tertiary Care Centre in Northern India: A Three-Year Retrospective Study. Cureus 2023; doi: 10.7759/cureus.46646
|
| 2 |
Akihiro Ohba, Chigusa Morizane, Makoto Ueno, Satoshi Kobayashi, Yasuyuki Kawamoto, Yoshito Komatsu, Masafumi Ikeda, Mitsuhito Sasaki, Naohiro Okano, Junji Furuse, Nobuyoshi Hiraoka, Hiroshi Yoshida, Aya Kuchiba, Ryo Sadachi, Kenichi Nakamura, Naoko Matsui, Yoshiaki Nakamura, Wataru Okamoto, Takayuki Yoshino, Takuji Okusaka. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncology 2022; 18(19): 2351 doi: 10.2217/fon-2022-0214
|
| 3 |
Ruud Weijer, Séverine Clavier, Esther A. Zaal, Maud M. E. Pijls, Robert T. van Kooten, Klaas Vermaas, René Leen, Aldo Jongejan, Perry D. Moerland, Antoine H. C. van Kampen, André B. P. van Kuilenburg, Celia R. Berkers, Simone Lemeer, Michal Heger. Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy. Cellular and Molecular Life Sciences 2017; 74(6): 1133 doi: 10.1007/s00018-016-2401-0
|
| 4 |
Audrey Clapéron, Martine Mergey, Thanh Huong Nguyen Ho-Bouldoires, Danijela Vignjevic, Dominique Wendum, Yves Chrétien, Fatiha Merabtene, Alexandra Frazao, Valérie Paradis, Chantal Housset, Nathalie Guedj, Laura Fouassier. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. Journal of Hepatology 2014; 61(2): 325 doi: 10.1016/j.jhep.2014.03.033
|
| 5 |
Attapol Titapun, Anchalee Techasen, Prakasit Sa-Ngiamwibool, Paiboon Sithithaworn, Vor Luvira, Tharatip Srisuk, Apiwat Jareanrat, Hasaya Dokduang, Watcharin Loilome, Bandit Thinkhamrop, Narong Khuntikeo. <p>Serum IgG as a Marker for <em>Opisthorchis viverrini</em>-Associated Cholangiocarcinoma Correlated with HER2 Overexpression</p>. International Journal of General Medicine 2020; : 1271 doi: 10.2147/IJGM.S282519
|
| 6 |
Audrey Clapéron, Martine Mergey, Lynda Aoudjehane, Thanh Huong Nguyen Ho-Bouldoires, Dominique Wendum, Aurélie Prignon, Fatiha Merabtene, Delphine Firrincieli, Christèle Desbois-Mouthon, Olivier Scatton, Filomena Conti, Chantal Housset, Laura Fouassier. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology 2013; 58(6): 2001 doi: 10.1002/hep.26585
|
| 7 |
Munita Meenu Bal, Mukta Ramadwar, Kedar Deodhar, Shailesh Shrikhande. Pathology of Gallbladder Carcinoma: Current Understanding and New Perspectives. Pathology & Oncology Research 2015; 21(3): 509 doi: 10.1007/s12253-014-9886-3
|
| 8 |
Ruud Weijer, Mans Broekgaarden, Milan Kos, Remko van Vught, Erik A.J. Rauws, Eefjan Breukink, Thomas M. van Gulik, Gert Storm, Michal Heger. Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery. Journal of Photochemistry and Photobiology C: Photochemistry Reviews 2015; 23: 103 doi: 10.1016/j.jphotochemrev.2015.05.002
|
| 9 |
Carolina Bizama, Patricia García, Jaime A. Espinoza, Helga Weber, Pamela Leal, Bruno Nervi, Juan Carlos Roa. Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treatment Reviews 2015; 41(3): 222 doi: 10.1016/j.ctrv.2015.01.003
|
| 10 |
Takamitsu Sasaki, Hiroki Kuniyasu, Yi Luo, Daisuke Kato, Satoshi Shinya, Kiyomu Fujii, Hitoshi Ohmori, Yuichi Yamashita. Significance of epithelial growth factor in the epithelial–mesenchymal transition of human gallbladder cancer cells. Cancer Science 2012; 103(6): 1165 doi: 10.1111/j.1349-7006.2012.02264.x
|
| 11 |
Eduardo E. Montalvo-Jave, Amir A. Rahnemai- Azar, Dimitrios Papaconstantinou, Mariana Espejel Deloiza, Diamantis I. Tsilimigras, Dimitrios Moris, German Eduardo Mendoza-Barrera, Sharon M. Weber, Timothy M. Pawlik. Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review. Surgical Oncology 2019; 31: 83 doi: 10.1016/j.suronc.2019.09.006
|
| 12 |
Giulia Grizzi, Michele Ghidini, Margherita Ratti, Marianna D’Ercole, Giulia Tanzi, Annalisa Abbiati, Andrea Celotti, Daniele Spada, Gian Luca Baiocchi, Maria Bonomi. Krukenberg Tumor Related to Gallbladder Cancer in a Young Woman: A Case Report and Review of the Literature. Journal of Personalized Medicine 2023; 13(6): 957 doi: 10.3390/jpm13060957
|
| 13 |
Changhe Zhang, Hong Xu, Zhenping Zhou, Ye Tian, Xiaofei Cao, Guochang Cheng, Qinghong Liu. Blocking of the EGFR‑STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6038
|
| 14 |
Lester Layfield. Role of Ancillary Techniques in Biliary Cytopathology Specimens. Acta Cytologica 2020; 64(1-2): 175 doi: 10.1159/000498976
|
| 15 |
Do-Youn Oh, Yung-Jue Bang. HER2-targeted therapies — a role beyond breast cancer. Nature Reviews Clinical Oncology 2020; 17(1): 33 doi: 10.1038/s41571-019-0268-3
|
| 16 |
Hee Jin Lee, Joon-Yong Chung, Stephen M. Hewitt, Eunsil Yu, Seung-Mo Hong. HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. Virchows Archiv 2012; 461(5): 521 doi: 10.1007/s00428-012-1321-0
|
| 17 |
A F Hezel, M S Noel, J N Allen, T A Abrams, M Yurgelun, J E Faris, L Goyal, J W Clark, L S Blaszkowsky, J E Murphy, H Zheng, A A Khorana, G C Connolly, O Hyrien, A Baran, M Herr, K Ng, S Sheehan, D J Harris, E Regan, D R Borger, A J Iafrate, C Fuchs, D P Ryan, A X Zhu. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. British Journal of Cancer 2014; 111(3): 430 doi: 10.1038/bjc.2014.343
|
| 18 |
JINGLI CAI, LUBAI XU, ZHENZHAI CAI, JISHENG WANG, BING ZHOU, HAI HU. MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor. Molecular Medicine Reports 2015; 12(1): 1549 doi: 10.3892/mmr.2015.3461
|
| 19 |
Nicola Fusco, Silvano Bosari. <i>HER2</i> aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. World Journal of Gastroenterology 2016; 22(35): 7926-7937 doi: 10.3748/wjg.v22.i35.7926
|
| 20 |
Siobhan C. McKay, Kristian Unger, Stephanos Pericleous, Gordon Stamp, Gerry Thomas, Robert R. Hutchins, Duncan R.C. Spalding. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB 2011; 13(5): 309 doi: 10.1111/j.1477-2574.2010.00286.x
|
| 21 |
Hyun-Jin Nam, Hwang-Phill Kim, Young-Kwang Yoon, Sang-Hyun Song, Ah-Rum Min, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang. The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Investigational New Drugs 2012; 30(6): 2148 doi: 10.1007/s10637-011-9782-6
|
| 22 |
Zongming E. Chen, Jeffrey Prichard, Fan Lin. Handbook of Practical Immunohistochemistry. 2015; : 503 doi: 10.1007/978-1-4939-1578-1_26
|
| 23 |
Karin Komposch, Maria Sibilia. EGFR Signaling in Liver Diseases. International Journal of Molecular Sciences 2015; 17(1): 30 doi: 10.3390/ijms17010030
|
| 24 |
Thomas Albrecht, Melina Rausch, Stephanie Rössler, Michael Albrecht, Jana Dorothea Braun, Veronika Geissler, Arianeb Mehrabi, Monika Nadja Vogel, Anita Pathil-Warth, Gunhild Mechtersheimer, Marcus Renner, Christian Rupp, Karl Heinz Weiss, Elena Busch, Bruno Köhler, Christoph Springfeld, Peter Schirmacher, Benjamin Goeppert. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6320-y
|
| 25 |
Michele A. Rodrigues, Dawidson A. Gomes, Ana Luiza Cosme, Marcelo Dias Sanches, Vivian Resende, Geovanni D. Cassali. Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4). Biomedicine & Pharmacotherapy 2022; 145: 112403 doi: 10.1016/j.biopha.2021.112403
|
| 26 |
Jeffrey Prichard, Fan Lin. Handbook of Practical Immunohistochemistry. 2011; : 389 doi: 10.1007/978-1-4419-8062-5_23
|
| 27 |
J Harder, G Ihorst, V Heinemann, R Hofheinz, M Moehler, P Buechler, G Kloeppel, C Röcken, M Bitzer, S Boeck, E Endlicher, A Reinacher-Schick, C Schmoor, M Geissler. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. British Journal of Cancer 2012; 106(6): 1033 doi: 10.1038/bjc.2012.18
|
| 28 |
Sagun Parakh, Hui K. Gan, Adam C. Parslow, Ingrid J.G. Burvenich, Antony W. Burgess, Andrew M. Scott. Evolution of anti-HER2 therapies for cancer treatment. Cancer Treatment Reviews 2017; 59: 1 doi: 10.1016/j.ctrv.2017.06.005
|
| 29 |
Junyao Xu, Jennifer J. Knox, Emin Ibrahimov, Eric Chen, Stefano Serra, Ming Tsao, Pinjiang Cao, Douglass Vines, David E. Green, Cristiane Metran-Nascente, Mairead G. McNamara, David W. Hedley. Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer. Clinical Cancer Research 2013; 19(1): 118 doi: 10.1158/1078-0432.CCR-12-2557
|
| 30 |
RODRIGO VIEIRA GOMES, MICHELE ÂNGELA RODRIGUES, JOÃO BERNARDO SANCIO ROCHA RODRIGUES, PAULA TEIXEIRA VIDIGAL, KARINE ARAÚJO DAMASCENO, HENRIQUE ARAÚJO LIMA, DAWIDSON ASSIS GOMES, CARLA JORGE MACHADO, VIVIAN RESENDE. Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival. Revista do Colégio Brasileiro de Cirurgiões 2018; 45(3) doi: 10.1590/0100-6991e-20181826
|
| 31 |
Rishit Mani, Amit Gupta, Sweety Gupta, Bela Goyal, Rahul Mishra, Amoli Tandon, Oshin Sharma, Kusum K Rohilla, Sanjeev Kishore, Puneet Dhar. Expression of ER, PR, and HER-2 Neu and correlation with tumor markers in gall bladder carcinoma. Journal of Cancer Research and Therapeutics 2023; 19(5): 1279 doi: 10.4103/jcrt.jcrt_1754_21
|
| 32 |
Beata Hryciuk, Rafał Pęksa, Michał Bieńkowski, Bartosz Szymanowski, Barbara Radecka, Kamil Winnik, Jolanta Żok, Natalia Cichowska, Mariola Iliszko, Renata Duchnowska. Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-58777-y
|
| 33 |
XIAOQING YANG, WEISHAN WANG, CHUNNI WANG, LIN WANG, MUYI YANG, MEI QI, HONG SU, XIUBIN SUN, ZHIYAN LIU, JUAN ZHANG, XIAOMIN QIN, BO HAN. Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncology Reports 2014; 32(2): 700 doi: 10.3892/or.2014.3261
|
| 34 |
Shou-Hua Wang, Fei Ma, Zhao-hui Tang, Xiao-Cai Wu, Qiang Cai, Ming-Di Zhang, Ming-Zhe Weng, Di Zhou, Jian-Dong Wang, Zhi-Wei Quan. Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in gallbladder cancer. Journal of Experimental & Clinical Cancer Research 2016; 35(1) doi: 10.1186/s13046-016-0436-6
|
| 35 |
Sanjeev K. Maurya, Mallika Tewari, Raghvendra R. Mishra, Hari S. Shukla. Genetic abberations in gallbladder cancer. Surgical Oncology 2012; 21(1): 37 doi: 10.1016/j.suronc.2010.09.003
|
| 36 |
Wenchao Gu, Shaocong Mo, Yulin Wang, Reika Kawabata-Iwakawa, Wei Zhang, Zongcheng Yang, Chenyu Sun, Yoshito Tsushima, Huaxiang Xu, Takahito Nakajima. Robust Validation and Comprehensive Analysis of a Novel Signature Derived from Crucial Metabolic Pathways of Pancreatic Ductal Adenocarcinoma. Cancers 2022; 14(7): 1825 doi: 10.3390/cancers14071825
|
| 37 |
Edward L Nelson. HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology. Clinical Investigation 2014; 4(8): 705 doi: 10.4155/cli.14.62
|
| 38 |
Yang Yang, Jigang Li, Lei Yao, Lile Wu. Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.710721
|
| 39 |
Andriana Inkoom, Nkafu Bechem Ndemazie, Taylor Smith, Esther Frimpong, Raviteja Bulusu, Rosemary Poku, Xue Zhu, Bo Han, Jose Trevino, Edward Agyare. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-10928-w
|
| 40 |
Jianhong Li, Zongming Eric Chen, Fan Lin. Handbook of Practical Immunohistochemistry. 2022; : 661 doi: 10.1007/978-3-030-83328-2_27
|
| 41 |
Behnaz Dolatabadi, Maryam Peymani, Leila Rouhi, Ali Salehzadeh, Kiavash Hushmandi, Mehrdad Hashemi. The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2. Molecular and Cellular Probes 2024; 78: 101985 doi: 10.1016/j.mcp.2024.101985
|
| 42 |
Patrick L. Garcia, Aubrey L. Miller, Tracy L. Gamblin, Leona N. Council, John D. Christein, J. Pablo Arnoletti, Marty J. Heslin, Sushanth Reddy, Joseph H. Richardson, Xiangqin Cui, Robert C.A.M. van Waardenburg, James E. Bradner, Eddy S. Yang, Karina J. Yoon. JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma. Molecular Cancer Therapeutics 2018; 17(1): 107 doi: 10.1158/1535-7163.MCT-16-0922
|
| 43 |
Masaaki Yokoyama, Hiroaki Ohnishi, Kouki Ohtsuka, Satsuki Matsushima, Yasuo Ohkura, Junji Furuse, Takashi Watanabe, Toshiyuki Mori, Masanori Sugiyama. KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers. Japanese Clinical Medicine 2016; 7 doi: 10.4137/JCM.S40549
|
| 44 |
Sirinapha Klungsaeng, Veerapol Kukongviriyapan, Auemduan Prawan, Sarinya Kongpetch, Laddawan Senggunprai. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells. The American Journal of Chinese Medicine 2020; 48(06): 1475 doi: 10.1142/S0192415X2050072X
|
| 45 |
Fnu Amisha, Paras Malik, Prachi Saluja, Nitesh Gautam, Tanvi Harishbhai Patel, Arya Mariam Roy, Sunny R. K. Singh, Sindhu Janarthanam Malapati. A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers. Onco 2023; 3(2): 96 doi: 10.3390/onco3020008
|
| 46 |
Takuya Kitamura, Jaya Srivastava, John DiGiovanni, Kaoru Kiguchi. Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer. Molecular Carcinogenesis 2015; 54(6): 459 doi: 10.1002/mc.22118
|
| 47 |
Sameer Gupta, Sudeep Garg, Vijay Kumar, Arun Chaturvedi, Sanjeev Misra, Naseem Akhtar, Shiv Rajan, Jatinder Kaur, Manikandan Lakshmanan, Kavitha Jain. Study of tumor transglutaminase 2 expression in gallbladder cancer – Is it a novel predictor of survival?. Annals of Hepato-Biliary-Pancreatic Surgery 2020; 24(4): 460 doi: 10.14701/ahbps.2020.24.4.460
|
| 48 |
Kunrui Zhu, Xinyi Yang, Hebei Tai, Xiaorong Zhong, Ting Luo, Hong Zheng. HER2-targeted therapies in cancer: a systematic review. Biomarker Research 2024; 12(1) doi: 10.1186/s40364-024-00565-1
|
| 49 |
Davendra P.S. Sohal, Shiva Shrotriya, Mohamed Abazeed, Michael Cruise, Alok Khorana. Molecular characteristics of biliary tract cancer. Critical Reviews in Oncology/Hematology 2016; 107: 111 doi: 10.1016/j.critrevonc.2016.08.013
|
| 50 |
Andriana Inkoom, Nkafu Ndemazie, Kevin Affram, Taylor Smith, Xue Zhu, Patrick Underwood, Sunil Krishnan, Edward Ofori, Bo Han, Jose Trevino, Edward Agyare. Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models. International Journal of Pharmaceutics: X 2020; 2: 100056 doi: 10.1016/j.ijpx.2020.100056
|
| 51 |
Nkafu Bechem Ndemazie, Andriana Inkoom, Dexter Ebesoh, Raviteja Bulusu, Esther Frimpong, Jose Trevino, Bo Han, Xue Zhu, Edward Agyare. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-10449-y
|
| 52 |
S.G. Barreto, A. Dutt, A. Chaudhary. A genetic model for gallbladder carcinogenesis and its dissemination. Annals of Oncology 2014; 25(6): 1086 doi: 10.1093/annonc/mdu006
|
| 53 |
Salvatore Galdy, Angela Lamarca, Mairéad G. McNamara, Richard A. Hubner, Chiara A. Cella, Nicola Fazio, Juan W. Valle. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. Cancer and Metastasis Reviews 2017; 36(1): 141 doi: 10.1007/s10555-016-9645-x
|
| 54 |
QING-FENG NI, JIA-WEI YU, FEI QIAN, NAI-ZHI SUN, JIAN-JIA XIAO, JIAN-WEI ZHU. Cortactin promotes colon cancer progression by regulating ERK pathway. International Journal of Oncology 2015; 47(3): 1034 doi: 10.3892/ijo.2015.3072
|
| 55 |
Abigale Lade, Satdarshan P. S. Monga. Molecular Pathology of Liver Diseases. Molecular Pathology Library 2011; 5: 291 doi: 10.1007/978-1-4419-7107-4_20
|
| 56 |
Caterina Peraldo-Neia, Giuliana Cavalloni, Elisabetta Fenocchio, Celeste Cagnazzo, Loretta Gammaitoni, Stefano Cereda, Guglielmo Nasti, Maria Antonietta Satolli, Giuseppe Aprile, Michele Reni, Antonio Avallone, Rosella Spadi, Tiziana Venesio, Vittoria Martin, Claudio Doglioni, Milo Frattini, Massimo Aglietta, Francesco Leone, John Souglakos. Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. PLOS ONE 2018; 13(1): e0191593 doi: 10.1371/journal.pone.0191593
|
| 57 |
Jason K. Sicklick, Paul T. Fanta, Kelly Shimabukuro, Razelle Kurzrock. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer and Metastasis Reviews 2016; 35(2): 263 doi: 10.1007/s10555-016-9602-8
|
| 58 |
Jesus M. Banales, Vincenzo Cardinale, Guido Carpino, Marco Marzioni, Jesper B. Andersen, Pietro Invernizzi, Guro E. Lind, Trine Folseraas, Stuart J. Forbes, Laura Fouassier, Andreas Geier, Diego F. Calvisi, Joachim C. Mertens, Michael Trauner, Antonio Benedetti, Luca Maroni, Javier Vaquero, Rocio I. R. Macias, Chiara Raggi, Maria J. Perugorria, Eugenio Gaudio, Kirsten M. Boberg, Jose J. G. Marin, Domenico Alvaro. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology & Hepatology 2016; 13(5): 261 doi: 10.1038/nrgastro.2016.51
|
| 59 |
Laura W. Goff, Dana B. Cardin, Jennifer G. Whisenant, Liping Du, Tatsuki Koyama, Kimberly B. Dahlman, Safia N. Salaria, Ruth T. Young, Kristen K. Ciombor, Jill Gilbert, Stephen James Smith, Emily Chan, Jordan Berlin. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Investigational New Drugs 2017; 35(1): 95 doi: 10.1007/s10637-016-0406-z
|
| 60 |
John D. Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R. Spigel, Christopher Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology 2018; 36(6): 536 doi: 10.1200/JCO.2017.75.3780
|
| 61 |
Atsuhiro Kojima, Juki Nakao, Naohiko Shimada, Naoki Yoshida, Yota Abe, Yu Mikame, Tsuyoshi Yamamoto, Takehiko Wada, Atsushi Maruyama, Asako Yamayoshi. Selective Photo-Crosslinking Detection of Methylated Cytosine in DNA Duplex Aided by a Cationic Comb-Type Copolymer. ACS Biomaterials Science & Engineering 2022; 8(5): 1799 doi: 10.1021/acsbiomaterials.2c00048
|
| 62 |
B. N. Gurmikov, D. V. Kalinin, I. G. Nikitin, T. A. Zhinzhilo, A. N. Shipilova, A. V. Chzhao. Frequency and effects of mutations in the KRAS gene on the survival of patients after surgical treatment of intrahepatic cholangiocarcinoma. Kuban Scientific Medical Bulletin 2020; 27(2): 59 doi: 10.25207/1608-6228-2020-27-2-59-69
|
| 63 |
Thomas Albrecht, Melina Rausch, Stephanie Roessler, Veronika Geissler, Michael Albrecht, Christine Halske, Carolin Seifert, Marcus Renner, Stephan Singer, Arianeb Mehrabi, Monika Nadja Vogel, Anita Pathil-Warth, Elena Busch, Bruno Köhler, Christian Rupp, Karl Heinz Weiss, Christoph Springfeld, Christoph Röcken, Peter Schirmacher, Benjamin Goeppert. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. Virchows Archiv 2020; 476(6): 871 doi: 10.1007/s00428-019-02706-6
|
| 64 |
Wei Zhou, Congqing Jiang, Nan Zhan, Xiaoguang Lv, Lifang Fan, Maskey Ninu. Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer. Journal of Cancer Research and Therapeutics 2018; 14(Suppl 1): S28 doi: 10.4103/0973-1482.206864
|
| 65 |
Kentaro Sawada, Yoshiaki Nakamura, Kohei Shitara. Development ofHER2-targeted Therapies for Gastrointestinal Cancer. European Oncology & Haematology 2020; 16(1): 29 doi: 10.17925/EOH.2020.16.1.29
|
| 66 |
Chae Hwa Kwon, Hyung Il Seo, Dong Uk Kim, Sung Yong Han, Suk Kim, So Jeong Lee, Da Ye Jeon. HER2 status based on breast cancer guidelines as a useful prognostic marker of T2 gallbladder cancer. European Journal of Surgical Oncology 2023; 49(2): 392 doi: 10.1016/j.ejso.2022.10.020
|
| 67 |
Alper Ata, Ayşe Polat, Ebru Serinsöz, Mehmet Ali Sungur, Ali Arican. Prognostıc Value of Increased her2 Expression in Cancers of Pancreas and Biliary Tree. Pathology & Oncology Research 2015; 21(3): 831 doi: 10.1007/s12253-014-9847-x
|
| 68 |
Heather Francis, Gianfranco Alpini, Sharon DeMorrow. Recent advances in the regulation of cholangiocarcinoma growth. American Journal of Physiology-Gastrointestinal and Liver Physiology 2010; 299(1): G1 doi: 10.1152/ajpgi.00114.2010
|
| 69 |
Lingli Chen, Lei Xu, Licheng Shen, Rongkui Luo, Dongxian Jiang, Yueqi Wang, Wei Li, Yingyong Hou. HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma. Frontiers in Genetics 2022; 12 doi: 10.3389/fgene.2021.831318
|
| 70 |
Hongsik Kim, Ryul Kim, Hye Ryeon Kim, Hyunji Jo, Hana Kim, Sang Yun Ha, Joon Oh Park, Young Suk Park, Seung Tae Kim. HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.834104
|
| 71 |
Pattaya Seeree, Phorutai Pearngam, Supeecha Kumkate, Tavan Janvilisri. An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. International Journal of Genomics 2015; 2015: 1 doi: 10.1155/2015/179528
|
| 72 |
Hasaya Dokduang, Wassana Jamnongkarn, Bundit Promraksa, Manida Suksawat, Sureerat Padthaisong, Malinee Thanee, Jutarop Phetcharaburanin, Nisana Namwat, Sakkarn Sangkhamanon, Attapol Titapun, Narong Khuntikeo, Poramate Klanrit, Watcharin Loilome. <p>In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines</p>. Drug Design, Development and Therapy 2020; : 2319 doi: 10.2147/DDDT.S250061
|
| 73 |
Taylor Smith, Kevin Affram, Ebony L. Nottingham, Bo Han, Felix Amissah, Sunil Krishnan, Jose Trevino, Edward Agyare. Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-73218-6
|
| 74 |
Jin Lee, Eun Hong, Jung Kim, Jung Kim, Jang Jung, Se Park, Dong Koh. Ursodeoxycholic acid inhibits epithelial‑mesenchymal transition, suppressing invasiveness of bile duct cancer cells: An in vitro study. Oncology Letters 2022; 24(6) doi: 10.3892/ol.2022.13568
|
| 75 |
Takamitsu Sasaki, Kuniyasu Hiroki, Yuichi Yamashita. The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment. BioMed Research International 2013; 2013: 1 doi: 10.1155/2013/546318
|
| 76 |
Milind Javle, Tanios Bekaii‐Saab, Apurva Jain, Ying Wang, Robin Katie Kelley, Kai Wang, Hyunseon C. Kang, Daniel Catenacci, Siraj Ali, Sunil Krishnan, Daniel Ahn, Andrea Grace Bocobo, Mingxin Zuo, Ahmed Kaseb, Vincent Miller, Philip J. Stephens, Funda Meric‐Bernstam, Rachna Shroff, Jeffrey Ross. Biliary cancer: Utility of next‐generation sequencing for clinical management. Cancer 2016; 122(24): 3838 doi: 10.1002/cncr.30254
|
| 77 |
Hui-Yi Feng, Yang-Chao Chen. Role of bile acids in carcinogenesis of pancreatic cancer: An old topic with new perspective. World Journal of Gastroenterology 2016; 22(33): 7463-7477 doi: 10.3748/wjg.v22.i33.7463
|
| 78 |
Thannicha Sae-Lao, Rutaiwan Tohtong, David O. Bates, Kanokpan Wongprasert. Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation. The American Journal of Chinese Medicine 2017; 45(03): 615 doi: 10.1142/S0192415X17500367
|
| 79 |
Raafat Alameddine, Patrick Mallea, Farhan Shahab, Yousef Zakharia. Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives. Current Treatment Options in Oncology 2023; 24(9): 1167 doi: 10.1007/s11864-023-01114-y
|
| 80 |
Darren Chyi-Hsiang Kong, Kenneth Yee Chew, Eng Tan, Suan Khoo. The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines. Cancer Cell International 2014; 14(1): 65 doi: 10.1186/1475-2867-14-65
|
| 81 |
Nobuyoshi Hiraoka, Hiroaki Nitta, Akihiro Ohba, Hiroshi Yoshida, Chigusa Morizane, Takuji Okusaka, Satoshi Nara, Minoru Esaki, Yoji Kishi, Kazuaki Shimada. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Human Pathology 2020; 105: 9 doi: 10.1016/j.humpath.2020.08.006
|
| 82 |
Patricia García, Carolina Bizama, Lorena Rosa, Jaime A. Espinoza, Helga Weber, Javier Cerda-Infante, Marianela Sánchez, Viviana P. Montecinos, Justo Lorenzo-Bermejo, Felix Boekstegers, Marcela Dávila-López, Francisca Alfaro, Claudia Leiva-Acevedo, Zasha Parra, Diego Romero, Sumie Kato, Pamela Leal, Marcela Lagos, Juan Carlos Roa. Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor. Biological Research 2020; 53(1) doi: 10.1186/s40659-020-00282-7
|
| 83 |
Sergio Renato PAIS-COSTA, José Francisco de Matos FARAH, Ricardo ARTIGIANI-NETO, Sandro José MARTINS, Alberto GOLDENBERG. Evaluation of P53, E-cadherin, Cox-2, and EGFR protein imunnoexpression on prognostic of resected gallbladder carcinoma. ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) 2014; 27(2): 126 doi: 10.1590/S0102-67202014000200009
|
| 84 |
Zichen Zhang, Regina A. Oyesanya, Deanna J. W. Campbell, Jorge A. Almenara, Jennifer L. DeWitt, Alphonse E. Sirica. Preclinical Assessment of Simultaneous Targeting of Epidermal Growth Factor Receptor (ERBB1) and ERBB2 as a Strategy for Cholangiocarcinoma Therapy†,‡. Hepatology 2010; 52(3): 975 doi: 10.1002/hep.23773
|
| 85 |
Norhayati Omar, Benedict Yan, Manuel Salto-Tellez. HER2: An emerging biomarker in non-breast and non-gastric cancers. Pathogenesis 2015; 2(3): 1 doi: 10.1016/j.pathog.2015.05.002
|
| 86 |
Min Yan, Barbara A. Parker, Richard Schwab, Razelle Kurzrock. HER2 aberrations in cancer: Implications for therapy. Cancer Treatment Reviews 2014; 40(6): 770 doi: 10.1016/j.ctrv.2014.02.008
|
| 87 |
Hiroshi Yoshida, Kazuaki Shimada, Tomoo Kosuge, Nobuyoshi Hiraoka. A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. Virchows Archiv 2016; 468(4): 431 doi: 10.1007/s00428-015-1898-1
|